fbpx
QQQ
-1.77
342.37
-0.52%
DIA
+ 2.04
334.76
+ 0.6%
SPY
+ 0.43
412.43
+ 0.1%
TLT
-0.62
139.10
-0.45%
GLD
-0.79
164.21
-0.48%

Why Stereotaxis, Inc. Common Stock's Stock is Trading Higher Today

February 25, 2021 10:24 am
Share to Linkedin Share to Twitter Share to Facebook Share to Print License More

Stereotaxis, Inc. Common Stock's Stock Price And Volume Action

Stereotaxis, Inc. Common Stock (AMEX:STXS) is currently up 6.02% to a price of $6.34. The stock's volume is currently 305.72 thousand, which is roughly 142.7% of its recent 30-day volume average of 214.24 thousand.

Why It's Moving

Benzinga Pro's real-time breaking news service shows some insight into what is affecting shares: Stereotaxis shares are trading higher after the company reported better-than-expected Q4 EPS and Sales results.

Further Analysis of Recent Price Action

The 50-day moving average price of Stereotaxis, Inc. Common Stock's stock was $5.09 when this article was published. The stock reached a high of $6.0 and a low of $1.7 in the past 52 weeks.

If you're looking for timely and concise explanations of why a stock is moving, check out Benzinga Pro. Subscribers get ‘Why Is It Moving' alerts as soon as our research team identifies the cause of the price action in a stock. Click here to learn more.

Posted-In:

Movers Trading Ideas

Related Articles

34 Stocks Moving in Tuesday's Pre-Market Session

Gainers Great Elm Group, Inc. (NASDAQ: GEG) shares rose 143.4% to $8.39 in pre-market trading after climbing around 15% on Monday. read more

Stocks That Hit 52-Week Highs On Friday

    Before 10 a.m. ET Friday, 39 stocks made new 52-week highs. read more

70 Biggest Movers From Yesterday

Gainers Pandion Therapeutics, Inc. (NASDAQ: PAND) shares surged 133.4% to close at $59.81 on Thursday after the company announced it will be acquired by Merck for $60 per share in cash. read more

52 Stocks Moving In Thursday's Mid-Day Session

Gainers Pandion Therapeutics, Inc. (NASDAQ: PAND) shares jumped 132% to $59.47 after the company announced it will be acquired by Merck for $60 per share in cash. read more